Chronic obstructive pulmonary disease combined with arterial hypertension: efficacy and safety ofthesustained-release indapamide (Arifon® retard)

Abstract

There is a problem of medicamental correction of arterial hypertension (AH) in patients with chronic obstructive lung disease (COLD), because number of drugs for the treatment of AH is limited in patients with bronchoobstractive diseases.The study shows that prolonged-release indapamide complex therapy is efficiency and safety (Arifon® retard) in patients with COLD associated with AH. The results demonstrate Arifon retard have positive effect on the AH: normalization of daily blood pressure (BP) profile and improvement of24-hour ambulatory blood pressure monitoring levels.At the same time it is shown that administration of Arifon retard does not affect the pulmonary ventilation rates (the results of the spirometry) and does not increase the lung hyperinflation (according to the results of Body plethysmography), and is not associated with hypokalaemia. The results of the study demonstrate that Arifon® retard can be used for safe correction of BP in patients with COLD associated with AH.

Keywords

• chronic obstructive lung disease
• arterial hypertension
• antihypertensive therapy
• prolonged-release indapamide
• arifon® retard
• efficiency
• safety